CO6900117A2 - Formulaciones peptídicas de liberación controlada - Google Patents
Formulaciones peptídicas de liberación controladaInfo
- Publication number
- CO6900117A2 CO6900117A2 CO13297046A CO13297046A CO6900117A2 CO 6900117 A2 CO6900117 A2 CO 6900117A2 CO 13297046 A CO13297046 A CO 13297046A CO 13297046 A CO13297046 A CO 13297046A CO 6900117 A2 CO6900117 A2 CO 6900117A2
- Authority
- CO
- Colombia
- Prior art keywords
- controlled release
- peptide formulations
- peptide
- formulations
- release
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161489886P | 2011-05-25 | 2011-05-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6900117A2 true CO6900117A2 (es) | 2014-03-20 |
Family
ID=46456496
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO13297046A CO6900117A2 (es) | 2011-05-25 | 2013-12-20 | Formulaciones peptídicas de liberación controlada |
Country Status (29)
Country | Link |
---|---|
US (2) | US11433120B2 (es) |
EP (1) | EP2714004B1 (es) |
JP (2) | JP6265888B2 (es) |
KR (1) | KR102066755B1 (es) |
CN (2) | CN108283619B (es) |
AR (1) | AR086577A1 (es) |
AU (2) | AU2012260821B2 (es) |
BR (1) | BR112013030104A8 (es) |
CA (1) | CA2836847C (es) |
CL (1) | CL2013003365A1 (es) |
CO (1) | CO6900117A2 (es) |
CR (1) | CR20130653A (es) |
CU (1) | CU20130158A7 (es) |
DK (1) | DK2714004T3 (es) |
DO (1) | DOP2013000275A (es) |
EA (1) | EA036213B1 (es) |
EC (1) | ECSP13013107A (es) |
FI (1) | FI2714004T3 (es) |
GT (1) | GT201300292A (es) |
IL (1) | IL229376B (es) |
MX (1) | MX361716B (es) |
MY (1) | MY177820A (es) |
NI (1) | NI201300127A (es) |
PE (1) | PE20141484A1 (es) |
PH (1) | PH12013502550B1 (es) |
SG (1) | SG194865A1 (es) |
TW (1) | TWI624271B (es) |
WO (1) | WO2012160213A1 (es) |
ZA (1) | ZA201309653B (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5127449B2 (ja) * | 2004-06-04 | 2013-01-23 | カムルス エービー | 流体デポ製剤 |
EP3563872A1 (en) | 2012-04-05 | 2019-11-06 | Massachusetts Institute Of Technology | Immunostimulatory compositions and methods of use thereof |
CA2874367C (en) * | 2012-05-25 | 2020-08-18 | Camurus Ab | Somatostatin receptor agonist formulations |
EP3791861A1 (en) | 2012-07-26 | 2021-03-17 | Camurus AB | Opioid formulations |
US10300145B2 (en) | 2016-07-15 | 2019-05-28 | Massachusetts Institute Of Technology | Synthetic nanoparticles for delivery of immunomodulatory compounds |
PT3512495T (pt) | 2016-09-15 | 2023-02-15 | Camurus Ab | Formulações análogas a prostaciclina |
IL295457A (en) | 2016-09-27 | 2022-10-01 | Camurus Ab | Mixtures and formulations containing alkyl ammonium salt edta |
CA3045114A1 (en) | 2016-12-07 | 2018-06-14 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
WO2019099735A1 (en) * | 2017-11-15 | 2019-05-23 | Rhythm Pharmaceuticals, Inc. | Sustained release peptide formulations |
CN109091451B (zh) * | 2018-09-10 | 2021-08-13 | 武汉百纳礼康生物制药有限公司 | 亲水性药物的油相液晶凝胶前体制剂及其制备方法 |
US20220202898A1 (en) * | 2019-05-29 | 2022-06-30 | Camurus Ab | Lipid-controlled release compositions |
CN113368041B (zh) * | 2020-07-17 | 2023-01-03 | 丽珠医药集团股份有限公司 | 药物组合物、缓释制剂及其制备方法 |
AU2022271139A1 (en) * | 2021-05-04 | 2023-10-12 | Camurus Ab | Compositions and methods for treating neuroendocrine tumors |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8865021B2 (en) * | 2003-11-07 | 2014-10-21 | Camurus Ab | Compositions of lipids and cationic peptides |
WO2006075124A1 (en) * | 2005-01-14 | 2006-07-20 | Camurus Ab | Somatostatin analogue formulations |
JP5127449B2 (ja) * | 2004-06-04 | 2013-01-23 | カムルス エービー | 流体デポ製剤 |
GB0412530D0 (en) * | 2004-06-04 | 2004-07-07 | Camurus Ab | Formulation |
CA2575906C (en) | 2004-08-04 | 2014-04-15 | Camurus Ab | Compositions forming non-lamellar dispersions |
GB0417388D0 (en) * | 2004-08-04 | 2004-09-08 | Camurus Ab | Composition |
SI1845942T1 (sl) * | 2005-01-14 | 2014-06-30 | Camurus Ab | Gnrh analogne formulacije |
KR101245022B1 (ko) * | 2005-01-21 | 2013-03-19 | 카무러스 에이비 | 약제학적 지질 조성물 |
CN101193652B (zh) * | 2005-04-08 | 2011-11-02 | 安米林药品公司 | 包含肠降血糖素肽和非质子极性溶剂的药物制剂 |
CA2609810C (en) * | 2005-06-06 | 2012-05-22 | Camurus Ab | Glp-1 analogue formulations |
GB0711656D0 (en) * | 2007-06-15 | 2007-07-25 | Camurus Ab | Formulations |
GB0716385D0 (en) * | 2007-08-22 | 2007-10-03 | Camurus Ab | Formulations |
GB0815435D0 (en) * | 2008-08-22 | 2008-10-01 | Camurus Ab | Formulations |
US8931272B2 (en) * | 2010-10-29 | 2015-01-13 | Ford Global Technologies, Llc | Method and system for limiting output of a boosted engine |
JP6081480B2 (ja) * | 2011-12-05 | 2017-02-15 | カムルス エービー | 頑強な徐放性製剤 |
CA2874367C (en) * | 2012-05-25 | 2020-08-18 | Camurus Ab | Somatostatin receptor agonist formulations |
US20230285502A1 (en) * | 2016-09-07 | 2023-09-14 | Camurus Ab | Mixtures and formulations |
IL295457A (en) * | 2016-09-27 | 2022-10-01 | Camurus Ab | Mixtures and formulations containing alkyl ammonium salt edta |
-
2012
- 2012-05-25 DK DK12731315.3T patent/DK2714004T3/da active
- 2012-05-25 FI FIEP12731315.3T patent/FI2714004T3/fi active
- 2012-05-25 PE PE2013002546A patent/PE20141484A1/es active IP Right Grant
- 2012-05-25 WO PCT/EP2012/059917 patent/WO2012160213A1/en active Application Filing
- 2012-05-25 EP EP12731315.3A patent/EP2714004B1/en active Active
- 2012-05-25 AU AU2012260821A patent/AU2012260821B2/en active Active
- 2012-05-25 EA EA201391675A patent/EA036213B1/ru not_active IP Right Cessation
- 2012-05-25 JP JP2014511911A patent/JP6265888B2/ja active Active
- 2012-05-25 KR KR1020137034307A patent/KR102066755B1/ko active IP Right Grant
- 2012-05-25 MX MX2013013401A patent/MX361716B/es active IP Right Grant
- 2012-05-25 TW TW101118843A patent/TWI624271B/zh active
- 2012-05-25 MY MYPI2013004227A patent/MY177820A/en unknown
- 2012-05-25 BR BR112013030104A patent/BR112013030104A8/pt not_active Application Discontinuation
- 2012-05-25 CN CN201810174910.XA patent/CN108283619B/zh active Active
- 2012-05-25 US US14/117,994 patent/US11433120B2/en active Active
- 2012-05-25 CN CN201280025151.1A patent/CN103702662B/zh active Active
- 2012-05-25 CA CA2836847A patent/CA2836847C/en active Active
- 2012-05-25 SG SG2013083019A patent/SG194865A1/en unknown
- 2012-05-28 AR ARP120101869A patent/AR086577A1/es unknown
-
2013
- 2013-11-11 IL IL22937613A patent/IL229376B/en active IP Right Grant
- 2013-11-22 GT GT201300292A patent/GT201300292A/es unknown
- 2013-11-22 DO DO2013000275A patent/DOP2013000275A/es unknown
- 2013-11-22 NI NI201300127A patent/NI201300127A/es unknown
- 2013-11-22 CL CL2013003365A patent/CL2013003365A1/es unknown
- 2013-11-25 CU CU2013000158A patent/CU20130158A7/es unknown
- 2013-12-09 PH PH12013502550A patent/PH12013502550B1/en unknown
- 2013-12-12 CR CR20130653A patent/CR20130653A/es unknown
- 2013-12-20 CO CO13297046A patent/CO6900117A2/es unknown
- 2013-12-20 ZA ZA2013/09653A patent/ZA201309653B/en unknown
- 2013-12-24 EC ECSP13013107 patent/ECSP13013107A/es unknown
-
2016
- 2016-04-06 AU AU2016202156A patent/AU2016202156B2/en active Active
-
2017
- 2017-11-29 JP JP2017228735A patent/JP6415673B2/ja active Active
-
2021
- 2021-06-17 US US17/350,363 patent/US20210308226A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6900117A2 (es) | Formulaciones peptídicas de liberación controlada | |
CO7000746A2 (es) | Formulaciones peptídicas robustas de liberación controlada | |
HK1212701A1 (zh) | 恩雜魯胺製劑 | |
SMT201600464B (it) | Procedimento per la preparazione di esterolo | |
CO6960555A2 (es) | Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas | |
BR112012030950A2 (pt) | formulações de vacina | |
DK2768479T3 (da) | Hjælpestoffer til nikotin-indeholdende terapeutiske sammensætninger | |
FI20116138L (fi) | Matriisi bioaktiivisten aineiden hallittuun vapauttamiseen | |
CO6801637A2 (es) | Formulaciones de anticuerpos | |
CO6950470A2 (es) | Formulaciones derivadas de decitabina | |
BR112013018951A2 (pt) | formulações de testosterona | |
CO6940426A2 (es) | Formulaciones farmacéuticas | |
SMT201600380B (it) | Formulazioni di darunavir | |
DE112012003251A5 (de) | Ausrücksystem | |
DE112012003262A5 (de) | Ausrücksystem | |
CO6940377A2 (es) | Formulaciones de liofilizadas de fgf-18 | |
FR2978964B1 (fr) | Composition vaccinale anti-il-6 | |
CO6801767A2 (es) | Formulaciones de liberación sostenida de paracetamol | |
DE112012003257A5 (de) | Ausrücksystem | |
CO6960544A2 (es) | Preparación de liberación sostenida | |
DK2672817T3 (da) | Forbedrede insekticide formuleringer | |
DK2694049T3 (da) | Tapentadol til forebyggelse af kronificering af smerte | |
DK2407155T3 (da) | Formuleringer af inecalcitol | |
DE112012003245A5 (de) | Ausrücksystem | |
HUE044183T2 (hu) | Kozmetikai ágensek nyújtott felszabadítására szolgáló rendszer |